Key result
Antithrombin agents such as hirudin and bivalirudin show efficacy in preventing deep venous thrombosis and treating acute coronary syndromes, though higher doses increase bleeding risk.
Why the study?
What is the role and efficacy of antithrombin agents in current antithrombotic therapy?
What is the role and efficacy of antithrombin agents in current antithrombotic therapy?
Answers are grounded in this paper and cite their sources.
Direct thrombin inhibitors like hirudin and bivalirudin offer effective alternatives to traditional anticoagulants in specific clinical scenarios, though bleeding risk remains a consideration.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
H.K. Breddin (2002) conducted a review in Thrombosis, acute coronary syndromes, heparin-induced thrombocytopenia. Antithrombin agents (hirudin, bivalirudin, argatroban, melagatran) was evaluated. Antithrombin agents such as hirudin and bivalirudin show efficacy in preventing deep venous thrombosis and treating acute coronary syndromes, though higher doses increase bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: